Literature DB >> 11137342

Potential inhibitory effects of formulation ingredients on intestinal cytochrome P450.

R J Mountfield1, S Senepin, M Schleimer, I Walter, B Bittner.   

Abstract

The use of common formulation ingredients (categorized into six groups) for preclinical animal studies has been assessed with respect to cytochrome P450 (CYP) inhibition, specifically CYP3A inhibition, in expressed human CYP3A4, human liver microsomes, dog- and cynomolgus monkey intestinal microsomes. Results indicated a wide range of inhibition potentials and there appeared to be species differences with inhibition of CYP3A activity. Generally, greater inhibition of CYP3A activity was observed with amphiphilic ingredients (for example mixed micellar solutions, Tween 80, and oleic acid). From the data presented, it can be predicted that the majority of the ingredients tested would not have a significant impact on the potential inhibition, by the formulation, on any apparent first pass metabolism in the intestinal tract for new drug entities being tested in the preclinical environment. However a number of common ingredients will require further investigation based on the estimated concentration within the gastrointestinal tract.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11137342     DOI: 10.1016/s0378-5173(00)00586-x

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  10 in total

Review 1.  Transforming lipid-based oral drug delivery systems into solid dosage forms: an overview of solid carriers, physicochemical properties, and biopharmaceutical performance.

Authors:  Angel Tan; Shasha Rao; Clive A Prestidge
Journal:  Pharm Res       Date:  2013-06-18       Impact factor: 4.200

2.  Evaluation of surfactants as solubilizing agents in microsomal metabolism reactions with lipophilic substrates.

Authors:  Kathleen Randall; Shun Wen Cheng; Anne Therese Kotchevar
Journal:  In Vitro Cell Dev Biol Anim       Date:  2011-09-05       Impact factor: 2.416

3.  Inhibitive effect of cremophor RH40 or tween 80-based self-microemulsiflying drug delivery system on cytochrome P450 3A enzymes in murine hepatocytes.

Authors:  Zichao Rao; Luqin Si; Yanbin Guan; Hongping Pan; Jun Qiu; Gao Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-11-10

4.  An in vitro examination of the impact of polyethylene glycol 400, Pluronic P85, and vitamin E d-alpha-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine.

Authors:  Brendan M Johnson; William N Charman; Christopher J H Porter
Journal:  AAPS PharmSci       Date:  2002

5.  Commonly used excipients modulate UDP-glucuronosyltransferase 2b7 activity to improve nalbuphine oral bioavailability in humans.

Authors:  Hong-Jaan Wang; Cheng-Huei Hsiong; Shung-Tai Ho; Min-Jen Lin; Tung-Yuan Shih; Pei-Wei Huang; Oliver Yoa-Pu Hu
Journal:  Pharm Res       Date:  2014-02-14       Impact factor: 4.200

6.  Hepatotoxicity after continuous amiodarone infusion in a postoperative cardiac infant.

Authors:  Jennifer S Kicker; Julie A Haizlip; Marcia L Buck
Journal:  J Pediatr Pharmacol Ther       Date:  2012-04

Review 7.  Polymers influencing transportability profile of drug.

Authors:  Vinod L Gaikwad; Manish S Bhatia
Journal:  Saudi Pharm J       Date:  2013-10       Impact factor: 4.330

8.  Febuxostat exerts dose-dependent renoprotection in rats with cisplatin-induced acute renal injury.

Authors:  Alaa N A Fahmi; George S G Shehatou; Abdelhadi M Shebl; Hatem A Salem
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-05-23       Impact factor: 3.000

Review 9.  Intestinal lymphatic transport for drug delivery.

Authors:  Jaime A Yáñez; Stephen W J Wang; Ian W Knemeyer; Mark A Wirth; Kevin B Alton
Journal:  Adv Drug Deliv Rev       Date:  2011-06-13       Impact factor: 15.470

10.  SNEDDS Containing Poorly Water Soluble Cinnarizine; Development and in Vitro Characterization of Dispersion, Digestion and Solubilization.

Authors:  Anne T Larsen; Anayo Ogbonna; Ragheb Abu-Rmaileh; Bertil Abrahamsson; Jesper Ostergaard; Anette Müllertz
Journal:  Pharmaceutics       Date:  2012-12-14       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.